Viking, Madrigal, Sanofi, Alnylam, Regeneron Q2 ’26 Earnings; Lilly Invests in KwikPen US Manufacturing Site; Verdiva Doses First Patient in Ph1 VRB-103 Study
A series of cardiometabolic-related news items has been observed from Viking Therapeutics, Madrigal Pharmaceuticals, Sanofi, Alnylam, Regeneron, Resilience/Lilly, and Verdiva Bio. Below, FENIX provides highlights and insights for the respective news items.
This content is for Read Less members only.
Already a member? Log in here